Groowe Groowe / Newsroom / PHIO
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

PHIO News

Phio Pharmaceuticals Corp. Common Stock

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 Ready to Announce with Confidence?

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

newsfilecorp.com
PHIO

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

newsfilecorp.com
PHIO

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

newsfilecorp.com
PHIO

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

newsfilecorp.com
PHIO